BIOMAT Database Logo BIOMAT Database Logo

Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase. 1. Tricyclic pyridobenzo- and dipyridodiazepinones. 1991

K D Hargrave, and J R Proudfoot, and K G Grozinger, and E Cullen, and S R Kapadia, and U R Patel, and V U Fuchs, and S C Mauldin, and J Vitous, and M L Behnke
Research and Development, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut 06877.

Novel pyrido[2,3-b][1,4]benzodiazepinones (I), pyrido[2,3-b][1,5]benzodiazepinones (II), and dipyrido[3,2-b:2',3'-e][1,4]diazepinones (III) were found to inhibit human immunodeficiency virus type 1 (HIV-1) reverse transcriptase in vitro at concentrations as low as 35 nM. In all three series, small substituents (e.g., methyl, ethyl, acetyl) are preferred at the lactam nitrogen, whereas slightly larger alkyl moieties (e.g., ethyl, cyclopropyl) are favored at the other (N-11) diazepinone nitrogen. In general, lipophilic substituents are preferred on the A ring, whereas substitution on the C ring generally reduces potency relative to the corresponding compounds with no substituents on the aromatic rings. Maximum potency is achieved with methyl substitution at the position ortho to the lactam nitrogen atom; however, in this case an unsubstituted lactam nitrogen is preferred. Additional substituents on the A ring can be readily tolerated. The dipyridodiazepinone derivative 11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido[3,2-b:2',3'-e] [1,4]diazepin-6-one (96, nevirapine) is a potent (IC50 = 84 nM) and and selective non-nucleoside inhibitor of HIV-1 reverse transcriptase, and has been chosen for clinical evaluation.

UI MeSH Term Description Entries
D011725 Pyridines Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
D002621 Chemistry A basic science concerned with the composition, structure, and properties of matter; and the reactions that occur between substances and the associated energy exchange.
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D001381 Azepines Seven membered heterocyclic rings containing a NITROGEN atom. Hexamethyleneimines
D001570 Benzodiazepinones
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D055598 Chemical Phenomena The composition, structure, conformation, and properties of atoms and molecules, and their reaction and interaction processes. Chemical Concepts,Chemical Processes,Physical Chemistry Concepts,Physical Chemistry Processes,Physicochemical Concepts,Physicochemical Phenomena,Physicochemical Processes,Chemical Phenomenon,Chemical Process,Physical Chemistry Phenomena,Physical Chemistry Process,Physicochemical Phenomenon,Physicochemical Process,Chemical Concept,Chemistry Process, Physical,Chemistry Processes, Physical,Concept, Chemical,Concept, Physical Chemistry,Concept, Physicochemical,Concepts, Chemical,Concepts, Physical Chemistry,Concepts, Physicochemical,Phenomena, Chemical,Phenomena, Physical Chemistry,Phenomena, Physicochemical,Phenomenon, Chemical,Phenomenon, Physicochemical,Physical Chemistry Concept,Physicochemical Concept,Process, Chemical,Process, Physical Chemistry,Process, Physicochemical,Processes, Chemical,Processes, Physical Chemistry,Processes, Physicochemical
D018894 Reverse Transcriptase Inhibitors Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template. Reverse Transcriptase Inhibitor,Inhibitors, Reverse Transcriptase,Inhibitor, Reverse Transcriptase,Transcriptase Inhibitor, Reverse
D019829 Nevirapine A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS. BI-RG-587,Nevirapine Hemihydrate,Viramune,BI RG 587,BIRG587,Hemihydrate, Nevirapine

Related Publications

K D Hargrave, and J R Proudfoot, and K G Grozinger, and E Cullen, and S R Kapadia, and U R Patel, and V U Fuchs, and S C Mauldin, and J Vitous, and M L Behnke
Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase. 2. Tricyclic pyridobenzoxazepinones and dibenzoxazepinones.
May 1992, Journal of medicinal chemistry,
K D Hargrave, and J R Proudfoot, and K G Grozinger, and E Cullen, and S R Kapadia, and U R Patel, and V U Fuchs, and S C Mauldin, and J Vitous, and M L Behnke
The QSAR analysis of tricyclic non-nucleoside inhibitors of HIV-1 reverse transcriptase.
January 2003, Acta poloniae pharmaceutica,
K D Hargrave, and J R Proudfoot, and K G Grozinger, and E Cullen, and S R Kapadia, and U R Patel, and V U Fuchs, and S C Mauldin, and J Vitous, and M L Behnke
Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
February 2004, Journal of medicinal chemistry,
K D Hargrave, and J R Proudfoot, and K G Grozinger, and E Cullen, and S R Kapadia, and U R Patel, and V U Fuchs, and S C Mauldin, and J Vitous, and M L Behnke
Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors: A Combinatorial Approach.
December 2017, Biochemistry. Biokhimiia,
K D Hargrave, and J R Proudfoot, and K G Grozinger, and E Cullen, and S R Kapadia, and U R Patel, and V U Fuchs, and S C Mauldin, and J Vitous, and M L Behnke
Next-generation HIV-1 non-nucleoside reverse transcriptase inhibitors.
February 2006, Current opinion in investigational drugs (London, England : 2000),
K D Hargrave, and J R Proudfoot, and K G Grozinger, and E Cullen, and S R Kapadia, and U R Patel, and V U Fuchs, and S C Mauldin, and J Vitous, and M L Behnke
Arylsulfone-based HIV-1 non-nucleoside reverse transcriptase inhibitors.
December 2013, Future medicinal chemistry,
K D Hargrave, and J R Proudfoot, and K G Grozinger, and E Cullen, and S R Kapadia, and U R Patel, and V U Fuchs, and S C Mauldin, and J Vitous, and M L Behnke
Dihydropyrimidinone-isatin hybrids as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.
February 2017, Bioorganic chemistry,
K D Hargrave, and J R Proudfoot, and K G Grozinger, and E Cullen, and S R Kapadia, and U R Patel, and V U Fuchs, and S C Mauldin, and J Vitous, and M L Behnke
Resistance to non-nucleoside inhibitors of HIV-1 reverse transcriptase.
February 1999, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy,
K D Hargrave, and J R Proudfoot, and K G Grozinger, and E Cullen, and S R Kapadia, and U R Patel, and V U Fuchs, and S C Mauldin, and J Vitous, and M L Behnke
QSAR for non-nucleoside inhibitors of HIV-1 reverse transcriptase.
September 2006, Bioorganic & medicinal chemistry,
K D Hargrave, and J R Proudfoot, and K G Grozinger, and E Cullen, and S R Kapadia, and U R Patel, and V U Fuchs, and S C Mauldin, and J Vitous, and M L Behnke
Discovery of Phenylaminopyridine Derivatives as Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors.
August 2012, ACS medicinal chemistry letters,
Copied contents to your clipboard!